JP2017526682A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526682A5
JP2017526682A5 JP2017511615A JP2017511615A JP2017526682A5 JP 2017526682 A5 JP2017526682 A5 JP 2017526682A5 JP 2017511615 A JP2017511615 A JP 2017511615A JP 2017511615 A JP2017511615 A JP 2017511615A JP 2017526682 A5 JP2017526682 A5 JP 2017526682A5
Authority
JP
Japan
Prior art keywords
antibody
drug
concentration
benzodiazepine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017511615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048152 external-priority patent/WO2016036861A1/en
Publication of JP2017526682A publication Critical patent/JP2017526682A/ja
Publication of JP2017526682A5 publication Critical patent/JP2017526682A5/ja
Withdrawn legal-status Critical Current

Links

JP2017511615A 2014-09-02 2015-09-02 抗体薬物複合体組成物の製剤化方法 Withdrawn JP2017526682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044592P 2014-09-02 2014-09-02
US62/044,592 2014-09-02
PCT/US2015/048152 WO2016036861A1 (en) 2014-09-02 2015-09-02 Methods for formulating antibody drug conjugate compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020082487A Division JP2020122012A (ja) 2014-09-02 2020-05-08 抗体薬物複合体組成物の製剤化方法

Publications (2)

Publication Number Publication Date
JP2017526682A JP2017526682A (ja) 2017-09-14
JP2017526682A5 true JP2017526682A5 (https=) 2018-10-11

Family

ID=55401285

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017511615A Withdrawn JP2017526682A (ja) 2014-09-02 2015-09-02 抗体薬物複合体組成物の製剤化方法
JP2020082487A Pending JP2020122012A (ja) 2014-09-02 2020-05-08 抗体薬物複合体組成物の製剤化方法
JP2020122719A Withdrawn JP2020172541A (ja) 2014-09-02 2020-07-17 抗体薬物複合体組成物の製剤化方法
JP2022010024A Withdrawn JP2022050688A (ja) 2014-09-02 2022-01-26 抗体薬物複合体組成物の製剤化方法
JP2024058979A Active JP7789826B2 (ja) 2014-09-02 2024-04-01 抗体薬物複合体組成物の製剤化方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020082487A Pending JP2020122012A (ja) 2014-09-02 2020-05-08 抗体薬物複合体組成物の製剤化方法
JP2020122719A Withdrawn JP2020172541A (ja) 2014-09-02 2020-07-17 抗体薬物複合体組成物の製剤化方法
JP2022010024A Withdrawn JP2022050688A (ja) 2014-09-02 2022-01-26 抗体薬物複合体組成物の製剤化方法
JP2024058979A Active JP7789826B2 (ja) 2014-09-02 2024-04-01 抗体薬物複合体組成物の製剤化方法

Country Status (13)

Country Link
US (4) US20160058884A1 (https=)
EP (2) EP3311846A1 (https=)
JP (5) JP2017526682A (https=)
KR (2) KR20240011258A (https=)
CN (3) CN106999604B (https=)
AU (2) AU2015311951B2 (https=)
CA (1) CA2958882A1 (https=)
HK (1) HK1254612A1 (https=)
IL (2) IL250768B (https=)
MA (2) MA40539A (https=)
RU (1) RU2741470C9 (https=)
SG (1) SG11201701328XA (https=)
WO (1) WO2016036861A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CN106999604B (zh) * 2014-09-02 2021-08-03 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
EP3769787A1 (en) * 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
JP7074749B2 (ja) 2016-06-07 2022-05-24 ナノファーマシューティカルズ エルエルシー αvβ3インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー
AU2017355402A1 (en) * 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
MA51629A (fr) * 2018-01-12 2020-11-18 Immunogen Inc Procédés de production, purification et formulation de conjugués anticorps-médicaments
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
WO2020223221A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
WO2021055894A1 (en) * 2019-09-19 2021-03-25 Janssen Biotech, Inc. Materials and methods for differential characterization of molecular conjugates and conjugation
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6995145B1 (en) * 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
WO2003072735A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL3524611T3 (pl) 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EA014640B1 (ru) 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8156876B2 (en) 2005-06-23 2012-04-17 Georgia Tech Research Corporation Systems and methods for integrated plasma processing of waste
MX2008002607A (es) 2005-08-22 2008-03-19 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
EP3539572A1 (en) * 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
SI1813614T1 (sl) * 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
ES2567402T3 (es) * 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008141278A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Method for preparing antibody conjugates
US7576505B2 (en) * 2007-06-21 2009-08-18 Jack Chen Device for finding a home position for a moveable member
US20090208979A1 (en) * 2008-02-14 2009-08-20 Technion Research And Development Foundation Ltd. Method for identifying antipsychotic drug candidates
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
NZ613647A (en) * 2009-05-06 2015-02-27 Biotest Ag Uses of immunoconjugates targeting cd138
TW201116297A (en) * 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
JP6049642B2 (ja) * 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
EP2694105A4 (en) * 2011-04-01 2015-04-29 Immunogen Inc CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
CN103648532A (zh) 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
WO2014055877A1 (en) * 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
BR112015019909A2 (pt) * 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
CN105592861A (zh) * 2013-08-02 2016-05-18 赛诺菲 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途
CN106999604B (zh) * 2014-09-02 2021-08-03 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
TW201609152A (zh) * 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
EP3189057A1 (en) * 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
JP2016052860A (ja) 2014-09-04 2016-04-14 株式会社東海理化電機製作所 タイヤ位置登録システム

Similar Documents

Publication Publication Date Title
JP2017526682A5 (https=)
Skidmore et al. ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1–resistant breast and gastric cancers
Abdollahpour‐Alitappeh et al. Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Yaghoubi et al. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
Maecker et al. Exploration of the antibody–drug conjugate clinical landscape
Stefan et al. Highly potent, anthracycline-based antibody–drug conjugates generated by enzymatic, site-specific conjugation
Lambert Drug‐conjugated antibodies for the treatment of cancer
Chari Targeted cancer therapy: conferring specificity to cytotoxic drugs
Khera et al. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates: E. Khera, GM Thurber
Sau et al. Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Lopus Antibody-DM1 conjugates as cancer therapeutics
Chari et al. Antibody–drug conjugates: an emerging concept in cancer therapy
Teicher et al. Antibody conjugate therapeutics: challenges and potential
Jain et al. Current ADC Linker Chemistry: Jain, Smith, Ghone and Tomczuk
Flygare et al. Antibody‐drug conjugates for the treatment of cancer
Alley et al. The pharmacologic basis for antibody-auristatin conjugate activity
JP6389446B2 (ja) 免疫複合体製剤
JP2020122012A5 (https=)
CN106999604B (zh) 用于配制抗体药物缀合物组合物的方法
Jackson et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates: Jackson and Stover
Govindan et al. Designing immunoconjugates for cancer therapy
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
RU2017102988A (ru) Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование
JP2014533954A5 (https=)
JP2016518332A5 (https=)